Screening and prevention strategies for endometrial cancer
Uterine Cancer Risk Reducing Strategies in Postmenopausal Women
This study is testing if screening and prevention strategies can help people at higher risk for endometrial cancer by identifying their risk and providing early care if needed.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Sex | Female |
| Sponsor | University of British Columbia Academic / other |
| Locations | 1 site (Vancouver, British Columbia) |
| Trial ID | NCT05651282 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility and acceptability of screening and risk-reducing interventions for individuals at increased risk of endometrial cancer. Participants will first complete a questionnaire to assess their absolute risk of developing endometrial cancer over the next decade. Those identified as high-risk will undergo a Progesterone Challenge Test to detect endometrial proliferation, followed by standard care if the test is positive. The study aims to improve early detection and prevention strategies for endometrial cancer.
Who should consider this trial
Good fit: Ideal candidates are postmenopausal individuals with an intact uterus who are at increased risk for endometrial cancer.
Not a fit: Patients currently undergoing hormone therapy or those with a history of abnormal uterine bleeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved screening and prevention methods for endometrial cancer, potentially reducing its incidence.
How similar studies have performed: Other studies have shown promise in using similar screening approaches for cancer prevention, indicating potential for success in this study.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Individuals are postmenopausal (must be three (3) years past last menstrual period) * Individuals have an intact uterus (have not had a hysterectomy) Exclusion Criteria: * Individuals taking hormone therapy for menopause (including vaginal estrogen) * Individuals taking male hormones, * Individuals on anti-endocrine therapy (such as tamoxifen) * Individuals on aromatase inhibitor therapy * Individuals who have experienced abnormal uterine bleeding * Individuals who have an Intrauterine Device (IUD)
Where this trial is running
Vancouver, British Columbia
- VGH Research Pavilion — Vancouver, British Columbia, Canada (Recruiting)
Study contacts
- Principal investigator: Aline Talhouk, PhD — University of British Columbia, Department of Obstetrics and Gynecology
- Study coordinator: Aline Talhouk, PhD
- Email: a.talhouk@ubc.ca
- Phone: +1 (604) 875-4111
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.